{"id":"icp-488","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hematologic toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ICP-488 selectively inhibits FLT3 (FMS-like tyrosine kinase 3) and related kinase pathways that drive proliferation in acute myeloid leukemia and other hematologic cancers. By blocking these oncogenic signaling pathways, the drug aims to suppress leukemic cell growth and induce apoptosis in FLT3-mutated or FLT3-ITD positive disease.","oneSentence":"ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:29.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia with FLT3 mutations"}]},"trialDetails":[{"nctId":"NCT07440537","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2026-03","conditions":"Cutaneous Lupus Erythematosus (CLE)","enrollment":105},{"nctId":"NCT06842199","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2025-03-20","conditions":"Plaque Psoriasis Patients","enrollment":383},{"nctId":"NCT06109818","phase":"PHASE2","title":"Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2024-01-04","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":129},{"nctId":"NCT05451199","phase":"PHASE1","title":"A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2022-07-29","conditions":"Psoriasis","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ICP-488","genericName":"ICP-488","companyName":"Beijing InnoCare Pharma Tech Co., Ltd.","companyId":"beijing-innocare-pharma-tech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies. Used for Acute myeloid leukemia with FLT3 mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}